CL2013002829A1 - Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. - Google Patents

Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Info

Publication number
CL2013002829A1
CL2013002829A1 CL2013002829A CL2013002829A CL2013002829A1 CL 2013002829 A1 CL2013002829 A1 CL 2013002829A1 CL 2013002829 A CL2013002829 A CL 2013002829A CL 2013002829 A CL2013002829 A CL 2013002829A CL 2013002829 A1 CL2013002829 A1 CL 2013002829A1
Authority
CL
Chile
Prior art keywords
hmpv
metapneumovirus
lyophilisate
antigens
adjuvant
Prior art date
Application number
CL2013002829A
Other languages
English (en)
Inventor
Ramirez Susan Marcela Bueno
Parra Alexis Mikes Kalergis
Beaumont Christian Palavecino
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Priority to CL2013002829A priority Critical patent/CL2013002829A1/es
Publication of CL2013002829A1 publication Critical patent/CL2013002829A1/es
Priority to GB1605054.4A priority patent/GB2532699B/en
Priority to CN201480060545.XA priority patent/CN105745323B/zh
Priority to DE112014004530.6T priority patent/DE112014004530T5/de
Priority to EP14850538.1A priority patent/EP3054013B1/en
Priority to US15/025,976 priority patent/US9999663B2/en
Priority to RU2016111978A priority patent/RU2665848C2/ru
Priority to KR1020167011372A priority patent/KR101822836B1/ko
Priority to MX2016003783A priority patent/MX2016003783A/es
Priority to PE2016000407A priority patent/PE20160536A1/es
Priority to ES14850538T priority patent/ES2853355T3/es
Priority to CA2925369A priority patent/CA2925369C/en
Priority to PCT/IB2014/064963 priority patent/WO2015049633A1/es
Priority to BR112016006989-7A priority patent/BR112016006989B1/pt
Priority to UY0001035765A priority patent/UY35765A/es
Priority to ARP140103655A priority patent/AR097881A1/es
Priority to ZA2016/02148A priority patent/ZA201602148B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE UNA FORMULACIÓN INMUNOGÉNICA QUE CONFIERE PROTECCIÓN CONTRA LA INFECCIÓN POR EL METAPNEUMOVIRUS (HMPV) Y/O ATENÚA LA PATOLOGÍA CAUSADA POR HMPV, QUE COMPRENDE UNA O MÁS CEPAS ATENUADAS DE MYCOBACTERIUM RECOMBINANTE EN UNA CANTIDAD QUE VA DE 10 4 A 10 9 BACTERIAS (CFU/DOSIS) POR CEPA, DONDE CADA CEPA EXPRESA LA PROTEÍNA P DE HMPV, O UN FRAGMENTO INMUNOGÉNICO DE ELLA, EN UN TAMPÓN SALINO FARMACOLÓGICAMENTE ACEPTABLE. ADEMÁS, LA INVENCIÓN DESCRIBE EL USO DE LA FORMULACIÓN INMUNOGÉNICA PARA PREPARAR UN MEDICAMENTO ÚTIL EN LA PREVENCIÓN DE LA ENFERMEDAD CAUSADA POR HMPV, O DE LA PATOLOGÍA PROVOCADA POR HMPV. FINALMENTE, LA INVENCIÓN DESCRIBE UNA VACUNA CONTRA HMPV, QUE COMPRENDE LA FORMULACIÓN INMUNOGÉNICA DESCRITA ANTERIORMENTE.
CL2013002829A 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. CL2013002829A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CL2013002829A CL2013002829A1 (es) 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
BR112016006989-7A BR112016006989B1 (pt) 2013-10-01 2014-09-30 Formulação imunogênica, uso de uma formulação imunogênica e vacina contra hmpv
RU2016111978A RU2665848C2 (ru) 2013-10-01 2014-09-30 Иммуногенная лекарственная композиция для медицинского использования, содержащая рекомбинант живой бцж, выделяющий антигены метапневмовируса (hmpv) в суспензию, приготовленную из лиофилизата без добавления адъюванта
MX2016003783A MX2016003783A (es) 2013-10-01 2014-09-30 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv), en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante, apta para su uso farmaceutico.
DE112014004530.6T DE112014004530T5 (de) 2013-10-01 2014-09-30 Immunogene Formulierung enthaltend einen rekombinanten lebenden BCG, welche Antigene von Metapneumovirus (HMPV) exprimiert, in einer aus einem Lyophilisat zubereiteten Suspension, ohne einen Hilfsstoff zu benötigen, welche geeignet für deren pharmazeutischen Verwendung ist
EP14850538.1A EP3054013B1 (en) 2013-10-01 2014-09-30 Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use
US15/025,976 US9999663B2 (en) 2013-10-01 2014-09-30 Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use
GB1605054.4A GB2532699B (en) 2013-10-01 2014-09-30 Immunogenic Formulation Comprising Live BCG Expressing hMPV P Proteins
KR1020167011372A KR101822836B1 (ko) 2013-10-01 2014-09-30 약제학적 사용에 적합한, 보조제를 요구하지 않는, 동결건조물로부터 준비된 현탁액 내의 메타뉴모바이러스 (hmpv)의 항원을 발현하는 재조합 생 bcg를 함유하는, 면역원성 제제
CN201480060545.XA CN105745323B (zh) 2013-10-01 2014-09-30 包含表达偏肺病毒(hMPV)抗原的重组活BCG的免疫原性制剂，其以无需佐剂地从冻干物制备的悬浮液形式存在并且适合于其制药用途
PE2016000407A PE20160536A1 (es) 2013-10-01 2014-09-30 FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE UN ADYUVANTE
ES14850538T ES2853355T3 (es) 2013-10-01 2014-09-30 Formulación inmunogénica que contiene BCG vivas recombinantes que expresan antígenos de Metapneumovirus (hMPV), en una suspensión que se prepara a partir de un liofilizado sin la necesidad de adyuvante, apta para su uso farmacéutico
CA2925369A CA2925369C (en) 2013-10-01 2014-09-30 Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use
PCT/IB2014/064963 WO2015049633A1 (es) 2013-10-01 2014-09-30 FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
ARP140103655A AR097881A1 (es) 2013-10-01 2014-10-01 FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO
UY0001035765A UY35765A (es) 2013-10-01 2014-10-01 FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
ZA2016/02148A ZA201602148B (en) 2013-10-01 2016-03-31 Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013002829A CL2013002829A1 (es) 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Publications (1)

Publication Number Publication Date
CL2013002829A1 true CL2013002829A1 (es) 2014-04-04

Family

ID=52778317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002829A CL2013002829A1 (es) 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Country Status (17)

Country Link
US (1) US9999663B2 (es)
EP (1) EP3054013B1 (es)
KR (1) KR101822836B1 (es)
CN (1) CN105745323B (es)
AR (1) AR097881A1 (es)
BR (1) BR112016006989B1 (es)
CA (1) CA2925369C (es)
CL (1) CL2013002829A1 (es)
DE (1) DE112014004530T5 (es)
ES (1) ES2853355T3 (es)
GB (1) GB2532699B (es)
MX (1) MX2016003783A (es)
PE (1) PE20160536A1 (es)
RU (1) RU2665848C2 (es)
UY (1) UY35765A (es)
WO (1) WO2015049633A1 (es)
ZA (1) ZA201602148B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133622A1 (es) * 2020-12-23 2022-06-30 Pontificia Universidad Catolica De Chile Formulación inmunogénica que contiene una o más cepas bcg modificadas que expresan una proteína de sars-cov-2, útil para prevenir, tratar o atenuar el desarrollo de covid-19.

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
CL2019003847A1 (es) * 2019-12-26 2021-08-06 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
CL2020002568A1 (es) * 2020-10-05 2022-08-05 Univ Pontificia Catolica Chile Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv
CN114767842A (zh) * 2022-04-29 2022-07-22 成都安永鼎业生物技术有限公司 一种重组卡介苗的冻干制剂及其制备方法和用途
CN114748615A (zh) * 2022-04-29 2022-07-15 成都安永鼎业生物技术有限公司 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
TWI344991B (en) * 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2008537683A (ja) 2005-01-12 2008-09-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 減弱されたヒトパラインフルエンザウイルス、その方法および使用
WO2008137981A1 (en) 2007-05-08 2008-11-13 Us Government As Represented By The Secy Of The Department Of Health And Human Services Human parainfluenza viruses having separated p and c genes
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
GB0809881D0 (en) * 2008-05-30 2008-07-09 Genomica Sau Method for detecting respiratory viral agents in a test sample

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133622A1 (es) * 2020-12-23 2022-06-30 Pontificia Universidad Catolica De Chile Formulación inmunogénica que contiene una o más cepas bcg modificadas que expresan una proteína de sars-cov-2, útil para prevenir, tratar o atenuar el desarrollo de covid-19.

Also Published As

Publication number Publication date
GB2532699A (en) 2016-05-25
GB2532699B (en) 2020-05-13
EP3054013A4 (en) 2016-08-31
ZA201602148B (en) 2017-06-28
PE20160536A1 (es) 2016-06-05
MX2016003783A (es) 2017-01-20
CA2925369C (en) 2020-09-22
ES2853355T3 (es) 2021-09-15
EP3054013B1 (en) 2020-11-11
US9999663B2 (en) 2018-06-19
KR20160058185A (ko) 2016-05-24
US20160220662A1 (en) 2016-08-04
KR101822836B1 (ko) 2018-01-29
CN105745323B (zh) 2020-09-04
BR112016006989A2 (pt) 2017-09-19
RU2016111978A (ru) 2017-11-10
UY35765A (es) 2015-04-30
CA2925369A1 (en) 2015-04-09
EP3054013A1 (en) 2016-08-10
WO2015049633A1 (es) 2015-04-09
RU2665848C2 (ru) 2018-09-04
GB201605054D0 (en) 2016-05-11
BR112016006989B1 (pt) 2023-10-17
CN105745323A (zh) 2016-07-06
DE112014004530T5 (de) 2016-10-06
AR097881A1 (es) 2016-04-20

Similar Documents

Publication Publication Date Title
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
UY35765A (es) FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112016025977A2 (pt) composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
JP2015527885A5 (es)
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
AR120887A1 (es) Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
MX2022000619A (es) Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad.
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
Ibragimova et al. Anthrax and the possibility of adsorption of natural zeolite